Cyclophosphamide versus placebo in scleroderma lung disease.
暂无分享,去创建一个
Charlie Strange | Robert Simms | Jonathan Goldin | Robert Elashoff | Robert Wise | John Varga | Kamal Mubarak | Birmingham | R. Elashoff | M. Roth | M. Mayes | J. Golden | J. Goldin | C. Strange | C. Read | D. Furst | R. Simms | J. Varga | R. Wise | V. Steen | P. Clements | J. Seibold | B. Fessler | V. Hsu | R. Silver | M. Olman | A. Theodore | M. Bolster | D. Tashkin | B. White | M. Metersky | Ángeles | F. Wigley | Daniel E Furst | Dean E Schraufnagel | N. Rothfield | Barbara White | Richard Silver | Philip J Clements | James R Seibold | Vivien M Hsu | D. Schraufnagel | Francisco | Donald P Tashkin | Michael D Roth | Edgar Arriola | Marcy Bolster | David J Riley | Arthur Theodore | Fredrick Wigley | Virginia Steen | Charles Read | Maureen Mayes | Ed Parsley | M Kari Connolly | Jeffrey Golden | Mitchell Olman | Barri Fessler | Naomi Rothfield | Mark Metersky | K. Mubarak | D. J. Riley | Michael D. Roth | E. Parsley | M. K. Connolly | George | M. Mayes | E. Arriola | Baltimore | Cal School | R. Johns | L. Angeles | Houston | D. Riley | M. Connolly | Hopkins School Of Medi-Cine | K. Uni | David J. Riley | Dean E. Schraufnagel | M. Kari Connolly | Daniel E. Furst | M. Mayes | Maureen D Mayes
[1] M. Mayes,et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. , 2001, Arthritis and rheumatism.
[2] C. Peppas,et al. Intravenous Cyclophosphamide Pulse Therapy for the Treatment of Lung Disease Associated with Scleroderma , 1999, Clinical Rheumatology.
[3] C. Wells,et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.
[4] J. Ioannidis,et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. , 2002, The Journal of rheumatology.
[5] D. Schoenfeld,et al. Combining mortality and longitudinal measures in clinical trials. , 1999, Statistics in medicine.
[6] Guy Hoffman,et al. Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis , 1996, Annals of Internal Medicine.
[7] A H Morris,et al. Standardized single breath normal values for carbon monoxide diffusing capacity. , 2015, The American review of respiratory disease.
[8] A. Lundin,et al. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. , 1994, Arthritis and rheumatism.
[9] Richard W. Martin,et al. Skin thickness score in systemic sclerosis , 1993 .
[10] R. Wise,et al. Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis , 2000, Annals of Internal Medicine.
[11] J. Hankinson,et al. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique--1995 update. , 1995, American journal of respiratory and critical care medicine.
[12] John L. Hankinson,et al. Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.
[13] P. J. Huber. Robust Regression: Asymptotics, Conjectures and Monte Carlo , 1973 .
[14] D. Mahler,et al. Minimal important difference of the transition dyspnoea index in a multinational clinical trial , 2003, European Respiratory Journal.
[15] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[16] T. Medsger,et al. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. , 1997, Arthritis and rheumatism.
[17] S. Jimenez,et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. , 1998, The Journal of rheumatology.
[18] T. Medsger,et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. , 1994, Arthritis and rheumatism.
[19] Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. , 1990, The American review of respiratory disease.
[20] J. Larson. The MOS 36-Item Short form Health Survey , 1997, Evaluation & the health professions.
[21] Physiologists. Guidelines for the measurement of respiratory function , 1994 .
[22] M Terrin,et al. Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.
[23] T. Medsger,et al. Severe restrictive lung disease in systemic sclerosis. , 1994, Arthritis and rheumatism.
[24] L. F. Black,et al. Maximal respiratory pressures: normal values and relationship to age and sex. , 2015 .
[25] R. Silver,et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. , 1993, The Journal of rheumatology.
[26] J. Vandenbroucke,et al. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. , 1983, Annals of the rheumatic diseases.
[27] B. Ferris,et al. Epidemiology Standardization Project (American Thoracic Society). , 1978, The American review of respiratory disease.
[28] C. McHorney,et al. The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs , 1993, Medical care.
[29] A. Wells,et al. Evaluation and management of alveolitis and interstitial lung disease in scleroderma , 2003, Current opinion in rheumatology.
[30] T. Petty. The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. , 1990, Chest.
[31] C. Kwoh,et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. , 1995, Arthritis and rheumatism.
[32] C. Vogelmeier,et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. , 1996, American journal of respiratory and critical care medicine.
[33] Ware J.E.Jr.,et al. THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .